"Spring break is on the way, or maybe summer vacation. Time to pack your swim suit, hit the beach, and perhaps indulge in a little harmless fun. What about getting a temporary tattoo to mark the occasion? Who could it hurt to get a temporary tatto"...
Application of Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch for longer duration than recommended, or the simultaneous or sequential application of multiple Synera (lidocaine and tetracaine) patches, could result in sufficient absorption of lidocaine and tetracaine to result in serious adverse effects (see OVERDOSAGE).
Even a used Synera patch contains a large amount of lidocaine and tetracaine (at least 90% of the initial amount). The potential exists for a child or pet to suffer serious adverse effects from chewing or ingesting a new or used Synera (lidocaine and tetracaine) patch. It is important for patients to store and dispose of Synera (lidocaine and tetracaine) out of the reach of children and pets.
Synera (lidocaine and tetracaine) should be used with caution in patients who may be more sensitive to the systemic effects of lidocaine and tetracaine including the acutely ill or debilitated.
Allergic or anaphylactoid reactions associated with lidocaine, tetracaine, or other components of Synera (lidocaine and tetracaine) can occur. They are characterized by urticaria, angioedema, bronchospasm, and shock. If an allergic reaction occurs, it should be managed by conventional means.
Contact of Synera (lidocaine and tetracaine) with the eyes should be avoided based on the findings of severe eye irritation with the use of similar products in animals. Also, the loss of protective reflexes may predispose to corneal irritation and potential abrasion. If eye contact occurs, immediately wash out the eye with water or saline and protect the eye until sensation returns.
Synera (lidocaine and tetracaine) is not recommended for use on mucous membranes or on areas with a compromised skin barrier because these uses have not been adequately studied. Application to broken or inflamed skin may result in toxic blood concentrations of lidocaine and tetracaine from increased absorption.
Patients with severe hepatic disease or pseudocholinesterase deficiency, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations of lidocaine and tetracaine.
Lidocaine has been shown to inhibit viral and bacterial growth. The effect of Synera (lidocaine and tetracaine) on intradermal injections of live vaccines has not been determined.
The integrated heating component contains iron powder, therefore, the Synera (lidocaine and tetracaine) patch must be removed before a patient undergoes magnetic resonance imaging.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenesis: Long-term studies in animals have not been performed to evaluate the carcinogenic potential of either lidocaine or tetracaine.
Mutagenesis: The mutagenic potential of lidocaine base and tetracaine base has been determined in the in vitro Ames Bacterial Reverse Mutation Assay, the in vitrochromosome aberration assay using Chinese hamster ovary cells, and the in vivo mouse micronucleus assay. Lidocaine was negative in all three assays. Tetracaine was negative in the in vitro Ames assay and the in vivo mouse micronucleus assay. In the in vitro chromosome aberration assay, tetracaine was negative in the absence of metabolic activation, and equivocal in the presence of metabolic activation.
Impairment of Fertility: Lidocaine did not affect fertility in female rats when given via continuous subcutaneous infusion via osmotic minipumps up to doses of 250 mg/kg/day (1500 mg/m2 or 43-fold higher than the single dermal administration [SDA]). Although lidocaine treatment of male rats increased the copulatory interval and lead to a dose-related decreased homogenization resistant sperm head count, daily sperm production, and spermatogenic efficiency, the treatment did not affect overall fertility in male rats when given subcutaneous doses up to 60 mg/kg (360 mg/m2 or 8-fold the SDA). Tetracaine did not affect fertility in male or female rats when given subcutaneous doses up to 7.5 mg/kg (45 mg/m2 or 1-fold the SDA). Multiples of exposure are based on a SDA of 70 mg each of lidocaine and tetracaine in Synera (lidocaine and tetracaine) patch for 30 minutes to a 60 kg person (43 mg/m2).
Use in Pregnancy
Pregnancy Category B. Lidocaine was not teratogenic in rats given subcutaneous doses up to 60 mg/kg (360 mg/m2 or 8-fold the SDA) or in rabbits up to 15 mg/kg (180 mg/m2 or 4-fold the SDA). Tetracaine was not teratogenic in rats given subcutaneous doses up to 10 mg/kg (60 mg/m2 or 1-fold the SDA) or in rabbits up to 5 mg/kg (60 mg/m2 or 1-fold the SDA). Synera components (lidocaine and tetracaine) given as a 1:1 eutectic mixture was not teratogenic in rats (60 mg/m2 or 1-fold the SDA) or rabbits (120 mg/m2 or 3-fold the SDA).
Lidocaine, contained 1:100,000 epinephrine, at a dose of 6 mg/kg (2-fold the SDA) injected into the masseter muscle of the jaw or into the gum of the lower jaw of Long-Evans hooded pregnant rats on gestation day 11 lead to developmental delays in neonatal behavior among offspring. Developmental delays were observed for negative geotaxis, static righting reflex, visual discrimination response, sensitivity and response to thermal and electrical shock stimuli, and water maze acquisition. The developmental delays of the neonatal animals were transient with responses becoming comparable to untreated animals later in life. The clinical relevance of the animal data is uncertain.
Pre- and postnatal maturational, behavioral, or reproductive development was not affected by maternal subcutaneous administration of tetracaine during gestation and lactation up to doses of 7.5 mg/kg (45 mg/m2 or 1-fold the SDA).
No adequate and well-controlled studies have been conducted in pregnant women. Because animal studies are not always predictive of human response, Synera (lidocaine and tetracaine) should be used during pregnancy only if the potential benefit justifies risk to the fetus.
Labor and Delivery
Neither lidocaine nor tetracaine is contraindicated in labor and delivery. In humans, the use of lidocaine for labor conduction analgesia has not been associated with an increased incidence of adverse fetal effects either during delivery or during the neonatal period. Tetracaine has also been used as a conduction anesthetic for cesarean section without apparent adverse effects on offspring. Should Synera (lidocaine and tetracaine) be used concomitantly with other products containing lidocaine and/or tetracaine, total doses contributed by all formulations must be considered.
Lidocaine is excreted into human milk and it is not known if tetracaine is excreted into human milk. Therefore, caution should be exercised when Synera (lidocaine and tetracaine) is administered to a nursing mother since the milk:plasma ratio of lidocaine is 0.4 and is not determined for tetracaine. In a prior report, when lidocaine was used as an epidural anesthetic for cesarean section in 27 women, a milk:plasma ratio of 1.07 ±0.82 was found by using AUC values. Following single dose administration of 20 mg of lidocaine for a dental procedure, the point value milk:plasma ratio was similarly reported as 1.1 at five to six hours after injection. Thus, the estimated maximum total daily dose of lidocaine delivered to the infant via breast milk would be approximately 36 µg/kg. Based on these data and the low concentrations of lidocaine and tetracaine found in the plasma after topical administration of Synera (lidocaine and tetracaine) in recommended doses, the small amount of these primary compounds and their metabolites that would be ingested orally by a suckling infant is unlikely to cause adverse effects (see CLINICAL PHARMACOLOGY, Pharmacokinetics).
The safety and effectiveness of Synera (lidocaine and tetracaine) have been established in pediatric patients 3 years and older based on adequate and well-controlled studies (see Clinical Studies). Safety has also been demonstrated in a clinical study in which 34 infants 4 to 6 months of age received Synera (lidocaine and tetracaine) . The recommended application time for the patch for pediatric patients is the same as for adults. Simultaneous or sequential application of more than two Synera (lidocaine and tetracaine) patches to children is not recommended as it has not been adequately studied.
Use in Geriatric Patients
In the controlled clinical studies, 139 patients over 65 years of age, including 41 patients over 75 years of age, received Synera (lidocaine and tetracaine) . VAS pain score differences between Synera (lidocaine and tetracaine) and placebo were considerably lower in the geriatric subjects than in the rest of the adult population. No overall differences in safety were observed between geriatric subjects and younger subjects. However, increased sensitivity in individual patients greater than 65 years of age cannot be ruled out. After intravenous dosing, the elimination half-life of lidocaine is significantly longer in elderly patients (2.5 hours) than in younger patients (1.5 hours).
Last reviewed on RxList: 1/23/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Synera Information
- Synera Drug Interactions Center: lidocaine-tetracaine top
- Synera Side Effects Center
- Synera FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.